Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 5:11 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 289–312 of 312 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Hypothalamic-pituitary Disorders Clear all
Completed Phase 3 Interventional Results available

Effect of Fluticasone Furoate Inhalation Powder on the Hypothalamic-pituitary-adrenocortical Axis of Children Aged 5-11 Years With Asthma

NCT02483975
View directory record Official record
Conditions
Asthma
Interventions
FF, Placebo, Montelukast, Albuterol/Salbutamol
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
5 Years to 11 Years
Enrollment
111 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
14
States / cities
Little Rock, Arkansas • Alhambra, California • Costa Mesa, California + 8 more
Source: ClinicalTrials.gov public record
Updated Apr 27, 2020 · Synced Oct 23, 2026, 5:11 AM EDT
Completed Phase 3 Interventional Results available

Compassionate Use of CORLUX® (Mifepristone) in the Treatment of Signs and Symptoms of Endogenous Cushing's Syndrome

NCT01371565
View directory record Official record
Conditions
Cushing's Disease, Cushing's Syndrome
Interventions
Mifepristone
Drug
Lead sponsor
Corcept Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
5
States / cities
Hollywood, Florida • Baltimore, Maryland • Ann Arbor, Michigan + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 18, 2014 · Synced Oct 23, 2026, 5:11 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Racial Discrimination and Stress Response

NCT05820659
View directory record Official record
Conditions
Stress Reaction; Acute
Interventions
peer rejection task, conversation about peer rejection, and impossible puzzle task
Behavioral
Lead sponsor
Western Kentucky University
Other
Eligibility
9 Years to 99 Years
Enrollment
178 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Bowling Green, Kentucky
Source: ClinicalTrials.gov public record
Updated Aug 17, 2026 · Synced Oct 23, 2026, 5:11 AM EDT
Completed Not applicable Interventional Results available

Double-Blind Placebo Controlled Study of Adjunctive Aripiprazole for Symptomatic Hyperprolactinemia In Premenopausal Women With Schizophrenia

NCT01338298
View directory record Official record
Conditions
Hyperprolactinemia
Interventions
Aripiprazole, Placebo
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
1
States / cities
Catonsville, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 27, 2019 · Synced Oct 23, 2026, 5:11 AM EDT
Completed Phase 2 Interventional

Evaluation of the Potential Effects of SSR149415 on the Hypothalamic-pituitary-adrenal Axis in Outpatients With Major Depressive Disorder

NCT01606384
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
VASOPRESSIN V1B RECEPTOR ANTAGONIST (SSR149415), Placebo
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 64 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated May 25, 2012 · Synced Oct 23, 2026, 5:11 AM EDT
Completed Phase 2 Interventional Results available

Targeted Therapy With Lapatinib in Patients With Recurrent Pituitary Tumors Resistant to Standard Therapy

NCT00939523
View directory record Official record
Conditions
Pituitary Adenomas, Prolactinomas
Interventions
Lapatinib
Drug
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2018
U.S. locations
3
States / cities
Los Angeles, California • Baltimore, Maryland • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 22, 2020 · Synced Oct 23, 2026, 5:11 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

A Prospective Study of Outcome After Therapy for Acromegaly

NCT01809808
View directory record Official record
Conditions
Acromegaly
Interventions
Surgery for acromegaly, Medications for acromegaly, Total body magnetic resonance imaging, Adipose Tissue Biopsy
Procedure · Drug · Diagnostic Test
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older
Enrollment
280 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2025
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 26, 2025 · Synced Oct 23, 2026, 5:11 AM EDT
Completed Phase 3 Interventional Results available

Patient Perception of Treatment Burden in Weekly Versus Daily Growth Hormone Injections in Children With GHD

NCT03831880
View directory record Official record
Conditions
Growth Hormone Deficiency
Interventions
Genotropin, somatrogon
Drug
Lead sponsor
Pfizer
Industry
Eligibility
3 Years to 17 Years
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
18
States / cities
Sacramento, California • Aurora, Colorado • Centennial, Colorado + 11 more
Source: ClinicalTrials.gov public record
Updated Oct 14, 2021 · Synced Oct 23, 2026, 5:11 AM EDT
Completed Phase 3 Interventional

Efficacy and Safety of SR121463B in Patients With Syndrome of Inappropriate Antidiuretic Hormone Secretion

NCT00264927
View directory record Official record
Conditions
Inappropriate ADH Syndrome, Hyponatremia
Interventions
SR121463B
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Dec 10, 2008 · Synced Oct 23, 2026, 5:11 AM EDT
Terminated Phase 2 Interventional Results available

Rosiglitazone in Treating Patients With Pituitary Tumors

NCT00616642
View directory record Official record
Conditions
Brain and Central Nervous System Tumors
Interventions
rosiglitazone maleate
Drug
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years to 65 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Aug 14, 2020 · Synced Oct 23, 2026, 5:11 AM EDT
Completed Phase 2 Interventional Results available

Study to Evaluate CORT125134 in Participants With Cushing's Syndrome

NCT02804750
View directory record Official record
Conditions
Cushing's Syndrome
Interventions
CORT125134
Drug
Lead sponsor
Corcept Therapeutics
Industry
Eligibility
18 Years to 80 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
12
States / cities
Laguna Hills, California • Aurora, Colorado • Fort Lauderdale, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2019 · Synced Oct 23, 2026, 5:11 AM EDT
Completed Phase 3 Interventional Results available

A Long-Term Trial Investigating Safety and Efficacy of TransCon hGH in Children With Growth Hormone Deficiency Who Have Completed a Prior TransCon hGH Clinical Trial

NCT03344458
View directory record Official record
Conditions
Growth Hormone Deficiency, Pediatric, Endocrine System Diseases, Hormone Deficiency, Pituitary Diseases
Interventions
TransCon hGH
Drug
Lead sponsor
Ascendis Pharma A/S
Industry
Eligibility
1 Year to 18 Years
Enrollment
298 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
22
States / cities
Birmingham, Alabama • Los Angeles, California • Orange, California + 18 more
Source: ClinicalTrials.gov public record
Updated Jul 7, 2026 · Synced Oct 23, 2026, 5:11 AM EDT
Completed Phase 1 Interventional

MS-275 in Treating Patients With Advanced Solid Tumors or Lymphoma

NCT00020579
View directory record Official record
Conditions
Cancer
Interventions
entinostat
Drug
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2008
U.S. locations
3
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 15, 2012 · Synced Oct 23, 2026, 5:11 AM EDT
Terminated Phase 2 Interventional

ALXN2420 Versus Placebo in Combination With Somatostatin Analogs in Participants With Acromegaly

NCT07037420
View directory record Official record
Conditions
Acromegaly
Interventions
ALXN2420, Placebo
Drug
Lead sponsor
Alexion Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
2
States / cities
Torrance, California • Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Aug 7, 2026 · Synced Oct 23, 2026, 5:11 AM EDT
Completed Phase 3 Interventional Results available

Assessment of the Ability of Subjects With Acromegaly or Their Partners to Administer Somatuline Autogel

NCT00447499
View directory record Official record
Conditions
Acromegaly
Interventions
Somatuline Autogel (lanreotide acetate), Home administration
Drug · Behavioral
Lead sponsor
Ipsen
Industry
Eligibility
18 Years and older
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
13
States / cities
La Mesa, California • Los Angeles, California • Denver, Colorado + 8 more
Source: ClinicalTrials.gov public record
Updated Nov 20, 2020 · Synced Oct 23, 2026, 5:11 AM EDT
Completed Phase 3 Interventional

A Trial to Assess the Long-term Safety of Octreotide Subcutaneous Depot in Patients With Acromegaly

NCT04125836
View directory record Official record
Conditions
Acromegaly
Interventions
CAM2029 (octreotide subcutaneous depot)
Drug
Lead sponsor
Camurus AB
Industry
Eligibility
18 Years and older
Enrollment
135 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
12
States / cities
Los Angeles, California • Palo Alto, California • Miami, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Dec 22, 2025 · Synced Oct 23, 2026, 5:11 AM EDT
Completed No phase listed Observational

Defining the Genetic Basis for the Development of Primary Pigmented Nodular Adrenocortical Disease (PPNAD) and the Carney Complex

NCT00001452
View directory record Official record
Conditions
Cushing's Syndrome, Pituitary Adenoma, Carney Complex, Primary Pigmented Nodular Adrenocortical Disease, Peutz-Jeghers Syndrome
Interventions
oCRH
Drug
Lead sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
Eligibility
3 Years to 70 Years
Enrollment
1,387 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1995
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 23, 2026, 5:11 AM EDT
Completed No phase listed Observational

Copeptin as a Biomarker for Central Diabetes Insipidus Development Following Pituitary Surgery

NCT04369703
View directory record Official record
Conditions
Sellar and Suprasellar Masses, Pituitary Tumor
Interventions
Not listed
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 95 Years
Enrollment
199 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 3, 2022 · Synced Oct 23, 2026, 5:11 AM EDT
Terminated No phase listed Observational

A Study to Confirm Recurrent or Persistent Cushing's Syndrome in Patients With Signs or Symptoms of Hypercortisolemia

NCT00796783
View directory record Official record
Conditions
Cushing's Syndrome
Interventions
Cushing's syndrome confirmation
Drug
Lead sponsor
Corcept Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2009
U.S. locations
3
States / cities
Escondido, California • Hollywood, Florida • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jun 20, 2014 · Synced Oct 23, 2026, 5:11 AM EDT
Completed Phase 4 Interventional Results available

Growth Hormone and Endothelial Function in Children

NCT00373386
View directory record Official record
Conditions
Growth Hormone Deficiency, Panhypopituitarism, Short Stature
Interventions
growth hormone
Drug
Lead sponsor
Ohio State University
Other
Eligibility
8 Years to 18 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated May 30, 2018 · Synced Oct 23, 2026, 5:11 AM EDT
Completed Phase 4 Interventional

A Study To Compare The Efficacy And Safety Of Pegvisomant To That Of Sandostatin Lar Depot In Patients With Acromegaly

NCT00068042
View directory record Official record
Conditions
Acromegaly
Interventions
Pegvisomant, Sandostatin LAR
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
13
States / cities
Los Angeles, California • Chicago, Illinois • Boston, Massachusetts + 8 more
Source: ClinicalTrials.gov public record
Updated Apr 7, 2008 · Synced Oct 23, 2026, 5:11 AM EDT
Completed Phase 1 Interventional

Acupuncture to Reduce Symptoms of Advanced Colorectal Cancer

NCT00034034
View directory record Official record
Conditions
Colorectal Neoplasms
Interventions
Acupuncture
Procedure
Lead sponsor
National Center for Complementary and Integrative Health (NCCIH)
NIH
Eligibility
18 Years and older
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2006
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 5, 2007 · Synced Oct 23, 2026, 5:11 AM EDT
Not listed No phase listed Observational Accepts healthy volunteers

Measurement of Outcome of Surgical Treatment in Patients With Acromegaly

NCT00005100
View directory record Official record
Conditions
Acromegaly
Interventions
Not listed
Lead sponsor
National Center for Research Resources (NCRR)
NIH
Eligibility
20 Years to 75 Years
Enrollment
165 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 1999
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 23, 2026, 5:11 AM EDT
Not listed No phase listed Observational

Characterization of Receptors in Non-functioning Pituitary Macroadenomas

NCT00852501
View directory record Official record
Conditions
Pituitary Tumor
Interventions
To perform RT-PCR on the tissue obtained during surgery
Other
Lead sponsor
Cook County Health
Government
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2013
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 9, 2013 · Synced Oct 23, 2026, 5:11 AM EDT